Psychosis Risk in Psychedelic Therapy: Systematic Review Insights (Global, 1984–2025)

Systematic Review Finds Low Psychosis Risk in Controlled Psychedelic Therapy

A systematic review published on October 27, 2026, synthesizes evidence from 52 studies conducted between 1984 and 2025, concluding that the risk of prolonged psychosis following psychedelic use is very low in rigorously controlled clinical settings. The review, available via OpenAlex, analyzed larger-scale population studies, clinical trials, emergency department reports, and case studies focusing on classic psychedelics such as psilocybin, LSD (lysergic acid diethylamide), DMT (N,N-dimethyltryptamine), and mescaline. Notably, among all controlled clinical trials reviewed, only one case of transient delusions was reported, and no persistent psychotic disorders were documented under clinical supervision. This finding directly addresses longstanding concerns about the psychiatric safety profile of psychedelic-assisted therapy.

Mechanisms and Context: Screening, Supervision, and Population Risk

The review identifies several mechanisms that mitigate psychosis risk in clinical settings, with rigorous pre-treatment screening and professional supervision being paramount. Of the 34 case reports examined, 58% involved individuals with a personal or family history of psychosis, highlighting genetic or pre-existing vulnerability as a major risk factor. In contrast, population-based data from studies involving over 100,000 individuals found no consistent correlation between lifetime psychedelic use and psychosis, suggesting that broad population risk is minimal. However, emergency and toxicology reports—often cited in media coverage—show higher rates of acute psychotic symptoms, likely reflecting selection bias toward more severe, unsupervised cases. Importantly, the review notes that first-episode psychosis, while rare, can occur in otherwise healthy individuals, underscoring the need for ongoing vigilance in screening protocols.

Policy and Clinical Implications: Toward Risk Stratification and Best Practices

These findings have direct implications for clinical practice, research protocols, and regulatory frameworks as psychedelic therapies move toward broader clinical adoption. The evidence base supports the implementation of robust risk stratification protocols, including comprehensive psychiatric history assessments and clear exclusion criteria for individuals with personal or familial psychosis risk. For policymakers, the data reinforce the necessity of maintaining clinical oversight and trained supervision as a non-negotiable standard for psychedelic-assisted therapy. Regulatory agencies and professional bodies may leverage these results to inform best practices, credentialing requirements, and post-marketing surveillance as access to psychedelic therapies expands beyond research settings.

• Concrete Example: A notable insight from the review is that even in large-scale population studies, the absence of a consistent association between psychedelics and psychosis suggests that broad-based restrictions may not be warranted if clinical safeguards are in place. This challenges the rationale for blanket prohibitions and supports a more nuanced, risk-based regulatory approach.

Risks, Unknowns, and Failure Modes: What Remains Unclear?

While the overall risk of prolonged psychosis is low in supervised settings, several important unknowns and potential failure modes remain. Causality between psychedelic use and psychosis is difficult to establish, particularly in naturalistic or recreational contexts where confounding variables abound. The review highlights that emergency department data likely overestimate risk due to selection bias, but also cautions that rare cases of first-episode psychosis in healthy individuals cannot be entirely ruled out. Furthermore, the expansion of psychedelic access—especially in jurisdictions experimenting with decriminalization or non-medical models—raises concerns about the adequacy of screening and supervision outside formal clinical trials. The review calls for the adoption of clear diagnostic parameters and ongoing monitoring of adverse psychiatric outcomes as therapies scale.

Looking Forward: Research, Regulation, and Clinical Practice

As psychedelic-assisted therapies move from research to real-world clinical practice, the evidence from this systematic review supports a cautious but optimistic approach. The low incidence of psychosis in controlled settings justifies continued clinical innovation, provided that rigorous screening and oversight remain central. Future research should focus on refining risk prediction tools, monitoring outcomes in diverse populations, and developing protocols for early identification and management of adverse psychiatric events. Policymakers and clinical leaders face the challenge of balancing access with safety, ensuring that the lessons from decades of research inform the next phase of psychedelic medicine.

By Dr. Alex J. Monroe, MD, PhD. Reviewed by Dr. Lisa Chen, MD, October 2026. Research based on primary source: OpenAlex W7223890514.